Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST: Docetaxel and S-1 vs S-1 and Cisplatin in Stage III Gastric Cancer
NCT01283217Phase 3
Key facts
- Status
- Unknown
- Start
- Mar 2010
- Primary completion
- Mar 2016
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- Small Molecules
- Drugs
- docetaxel
- Conditions
- gastric adenocarcinoma
01
Overview
Phase 3, randomised, open-label trial of docetaxel in gastric adenocarcinoma, sponsored by Yonsei University. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Docetaxel was the first drug that showed survival benefits when added to the CF regimen, but it was very toxic. Docetaxel is also has a synergistic anti-cancer effect with S-1, in phase I/II studies. The use of a docetaxel plus S-1 combination as first-line chemotherapy for advanced gastric cancer achieved response rates of 46\~56% and a median survival time of 14.0\~14.3 months.
Based upon this background, the aim of this study is to detect a significant increase in 3 year DFS of disease for the test group (DS) relative to the Control group (SP).
Beyond the preview
Go deeper on NCT01283217.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283217.